Immunoblot Test Differentiates Pollen Allergies Diagnoses
By LabMedica International staff writers Posted on 28 Jun 2018 |
Image: Specific IgE antibodies against inhalation allergens that commonly occur in Southern Europe can be detected and differentiated using the new multiparameter immunoblot EUROLINE DPA-Dx Pollen Southern Europe (Photo courtesy of EUROIMMUN).
Specific immunoglobulin E (IgE) antibodies against inhalation allergens that commonly occur in Southern Europe can be detected and differentiated using a new multiparameter immunoblot test.
The test is based on defined partial allergens (DPA, allergen components) and the detailed profile identifies the precise allergy-causing proteins, distinguishing primary sensitizations from cross-reactions and thus aiding therapy decision-making.
The test is based on a unique combination of species-specific marker molecules, cross-reactive components and whole extracts, encompassing tree pollens (birch, olive, cypress, hazel, oak), grass pollens (timothy grass, wall pellitory) and the fungus Alternaria alternata. The native extracts provide a general screening for IgE antibodies against the respective pollen/fungus.
The multiparameter immunoblot EUROLINE DPA-Dx Pollen Southern Europe 1 test (EUROIMMUN AG, 23560 Luebeck, Germany) is a combination of the Southern European species-specific marker molecules together with common panallergens, such as PR-10 proteins and profilin, enables precise discrimination between a putative primary sensitization and a persistent cross reaction. Positive reactions with species-specific markers are an indication for specific immunotherapy. Positive reactions with panallergens on the other hand indicate cross-reactions. Cross-reactive molecules are prevalent among different types of plants, which often results in a high sensitization rate. An insufficient differentiation between primary sensitization and cross-reactions often results in a less effective desensitization during specific immunotherapy.
The test also includes a band of cross reactive carbohydrate determinants (CCD), which aids the differentiation of clinically relevant reactions from unspecific anti-CCD reactions and thus the interpretation of results. With this in-depth profile, true sensitizations can be reliably identified, enabling targeted selection of the most suitable specific immunotherapy and improved prognosis of the therapy success. The test is easy to perform and requires only a small sample volume. The high analytical and clinical value of the profile has been verified in an independent study. Automated processing and evaluation are available for the assay.
The test is based on defined partial allergens (DPA, allergen components) and the detailed profile identifies the precise allergy-causing proteins, distinguishing primary sensitizations from cross-reactions and thus aiding therapy decision-making.
The test is based on a unique combination of species-specific marker molecules, cross-reactive components and whole extracts, encompassing tree pollens (birch, olive, cypress, hazel, oak), grass pollens (timothy grass, wall pellitory) and the fungus Alternaria alternata. The native extracts provide a general screening for IgE antibodies against the respective pollen/fungus.
The multiparameter immunoblot EUROLINE DPA-Dx Pollen Southern Europe 1 test (EUROIMMUN AG, 23560 Luebeck, Germany) is a combination of the Southern European species-specific marker molecules together with common panallergens, such as PR-10 proteins and profilin, enables precise discrimination between a putative primary sensitization and a persistent cross reaction. Positive reactions with species-specific markers are an indication for specific immunotherapy. Positive reactions with panallergens on the other hand indicate cross-reactions. Cross-reactive molecules are prevalent among different types of plants, which often results in a high sensitization rate. An insufficient differentiation between primary sensitization and cross-reactions often results in a less effective desensitization during specific immunotherapy.
The test also includes a band of cross reactive carbohydrate determinants (CCD), which aids the differentiation of clinically relevant reactions from unspecific anti-CCD reactions and thus the interpretation of results. With this in-depth profile, true sensitizations can be reliably identified, enabling targeted selection of the most suitable specific immunotherapy and improved prognosis of the therapy success. The test is easy to perform and requires only a small sample volume. The high analytical and clinical value of the profile has been verified in an independent study. Automated processing and evaluation are available for the assay.
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms